CD274 and non-small cell lung carcinoma: Considering that PD-1/PD-L1 checkpoint blockades have dramatically changed the treatment patterns for advanced non-small cell lung cancer (NSCLC), renal cancer, chronic Hodgkin’s lymphoma, gastric cancer, urothelial cancer, cervical cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, and melanoma [8–12], more explorations of immune checkpoint inhibitors in glioblastoma have been conducted.